Online inquiry

IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11272MR)

This product GTTS-WQ11272MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11272MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12295MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ11437MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ10323MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ4390MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12577MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ9633MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ15235MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ2017MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW